Search
This study aimed to determine factors associated with severe pertussis in hospitalized children during an epidemic using a novel pertussis severity scoring...
In the longest reported follow-up of infants who received aP vaccine at birth, we found a trend to lower PT IgG antibodies post booster compared with receipt...
Without a booster dose, the effectiveness of 3 doses waned more rapidly from 2 to 4 years of age than previously documented for children >6 years of age who...
Tiny babies could soon have much-needed protection from community transmission of potentially deadly whooping cough thanks to a world-first nasal spray vaccine being trialed at The Kids Research Institute Australia.
New collaborative research involving almost 600,000 pregnant mothers has demonstrated a dramatic increase in uptake of the whooping cough (pertussis) vaccine after identifying just 22 per cent of WA women had the maternal vaccination between 2012 – 2017.
Toddlers will now get an additional whooping cough vaccine to protect them against the potentially deadly disease.
An extra whooping cough vaccination for babies comes as a result of work by researchers at the Wesfarmers Centre of Vaccines and Infectious Diseases.
We compared the effect of a heterologous wP/aP/aP primary series (hereafter mixed wP/aP) versus a homologous aP/aP/aP primary schedule (hereafter aP-only) on antibody responses to co-administered vaccine antigens in infants and toddlers.
Whooping cough (pertussis) is a highly contagious respiratory infection which causes a severe cough and can be particularly dangerous to babies under a year old. Vaccination is the best way to reduce the risk of whooping cough.
Vaccination is the injection of an inactivated bacteria or virus into the body. This simulated infection allows an individual's immune system to develop an adaptive immunity for protection against that type of illness. When a sufficiently large percentage of a population has been vaccinated, this results in herd immunity.